-
Run away from the PD-L1 and the $10 billion double-resistant market Corning Jerry's IPO in Hong Kong today
Time of Update: 2021-03-04
01 Double Resistance Race: Another Upcoming According to the previously disclosed prospecto, Corning Jerry's current product pipeline includes eight tumor candidate drugs, four of which are in the clinical stage, with progress from Clinical Phase I to Critical Phase II/III.
-
Changchun Gaoxin threw 5.6 billion restructuring commitments to earn nearly 6 billion in three years
Time of Update: 2021-03-04
Data show that Jinsai Pharmaceuticals is mainly engaged in the research and development, production and sales of biopharmaceous products, the main products for injection recombinant human growth hormone, recombinant human growth hormone injection, polyethyl glycol recombinant human growth hormone injection, among which, recombinant human growth hormone injection sales in 2018 more than 2 billion yuan, gross margin of 96.97 percent.
-
Lepu Healthcare made a net profit of $1.2 billion from strong sales of bio-absorbable stents
Time of Update: 2021-03-04
the reasons for the first-half 2019 results growth, Lepu Medical said in a statement that its newly developed NeoVas bio-absorbable support, or NeoVas, has been contributing strong new earnings growth since it went on sale in late March.
-
The pay of 23 pharmaceutical companies was announced, with Murray the highest
Time of Update: 2021-03-04
It can be seen that, whether for executives or ordinary employees, Murray Medical and Fosun Pharma pay enough generous wages, can be described as the "best employer." ▍ Fosun Pharma: High executive pay, high proportion of research and development It is understood that Fosun Pharma is mainly to drug research and development and manufacturing as the core, at the same time in the pharmaceutical circulation, medical services, medical diagnostics and medical devices and other fields have a high market position.
-
High-value consumables new sharp Gligtai received 10 million levels of financing
Time of Update: 2021-03-04
(ligetai) received a new round of 10 million yuan financing, the investors for The Acquisition and Huitong.
This financing will continue to be used for the company's core product development.
-
The loss of the Yushatan storm is serious, can Huahai Pharmaceuticals get out of the difficult situation in 2019?
Time of Update: 2021-03-04
Huahai Pharmaceuticals currently business to specialty raw materials and preparations mainly, raw materials mainly include antihypertensive, psychotic and anti-AIDS and other characteristics of raw m
-
Kaiyu Bio completed tens of millions of yuan of round A financing for the main project preclinical development
Time of Update: 2021-03-04
Kaihe Bio today announced the completion of tens of millions of yuan of round A financing, by Jundudi Investment and Vosseng Capital co-investment.
-
Fist products 50 million yuan transfer into the pharmaceutical industry or for the turnaround?
Time of Update: 2021-03-04
Shenzhen Stock Exchange issued a letter of concern to this, asking the dual-form pharmaceutical industry to explain the production and sales since the "Drug GMP Certificate" obtained in May this year, the specific impact of the relevant technology transfer on the company's performance and the company's proposed response measures.
-
Hebei consolidates and divides by drug supplements to speed up the construction of medical associations
Time of Update: 2021-03-04
same time, Hebei has accelerated the pace of medical association construction, implemented the functional orientation of various medical and health institutions at all levels, promoted inter-agency collaboration, and promoted the sinking of high-quality medical resources.
-
Companies such as Alibaba Cloud have announced advances in the medical layout of artificial intelligence
Time of Update: 2021-03-04
It is understood that Alibaba Cloud joint ecological partners from storage, sharing to intelligence, to provide cloud-to-cloud integrated image cloud solutions, can provide a large number of secure storage services, digital images can automatically multi-redundant backup, real-time access to historical images, interregional image connectivity, and so on.
-
Kyushua Pharmaceuticals' $790 million acquisition of Novaral's CDMO subsidiary is on fire!
Time of Update: 2021-03-04
After the acquisition is completed, the company will give full play to Suzhou Novarchi's core business advantages, optimize the company's core business advantages in areas such as innovative drug CDMO one-stop service, and meet China's fast-growing commissioned research and development and production needs, Kyushua Pharmaceuticals said in a statement.
-
Step Pharmaceuticals set up a number of subsidiaries will transform scientific research
Time of Update: 2021-03-04
public opinion dispersed, step-by-step pharmaceutical voice, will transform scientific research, get rid of the marketing-oriented pharmaceutical company image. ▍ from marketing to scientific resea
-
Chongqing Pharma acquired an 87.47% stake in the subsidiary
Time of Update: 2021-03-04
On December 16, Tiansli announced that it had signed a Framework Agreement with Chongqing Pharmaceuticals (Group) Co., Ltd.
("Chongqing Pharmaceuticals") to sell its controlling subsidiary, Tianjin Tiansli Pharmaceutical Marketing Group Co., Ltd.
-
Innovative medicine blows! Hengrui's half-year revenue of 10 billion Chinese biopharmaceuticals 12.5 billion
Time of Update: 2021-03-04
In fact, as the largest pharmaceutical company by market capitalization in China, Hengrui Pharmaceuticals has also begun to shift its research and development focus to innovative pharmaceuticals, according to the semi-annual report, in the first half of 2019 Hengrui Pharmaceuticals invested 1,484 million yuan in research and development, an increase of 49.13 percent over the same period last year, and the proportion of research and development investment in sales revenue reached 14.80 percent.
-
Aiji Taikang completed 50 million yuan B round of financing, Jinke Jun venture capital lead investment
Time of Update: 2021-03-04
Focusing on research and development innovations in high-volume sequencing target capture technology and the design and production of gene testing products, Aji taikang is a production service platform company driven by gene testing technology.
-
The sale of a stake in Harmony Hospital by Fosun Pharma's subsidiary has been completed
Time of Update: 2021-03-04
After delivery, Fosun Pharma Holdings holding 9.4 million shares of NFC (approximately 7.04% of the total number of enlarged shares of NFC as of December 18, 2019) and no longer directly holding a limited partnership interest in HHH and a stake in Healthy Harmony GP.
-
Sansheng Pharmaceuticals' first half 2019 results were announced
Time of Update: 2021-03-04
have also made significant progress: humanized anti-tumor necrotizing factors α anti-tumor necrotizing factors for patients with rheumatoid arthritis (RA) α antibody products (SSS07) have completed health volunteers and RA The first phase of clinical trials in patients is currently preparing for the second phase trial of RA patients and other inflammatory diseases, and the clinical trial of anti-IL-17A antibodies (608) for moderate-severe plaque-like psoriasis was approved by the National Drug Administration on July 31 this year.
-
Tianying Pharmaceuticals intends to set up a medical clinic management department
Time of Update: 2021-03-04
10 years of nine losses of the Tianmen pharmaceutical industry, this layout of rural medical care, whether to panic, or to renew the face, make a comeback?
-
Haizheng Pharmaceuticals gave a controlling stake in its subsidiary of $3.828 billion or eased its $10 billion debt
Time of Update: 2021-03-04
Recently, Haizheng Pharmaceuticals announced that the Taiwan Stock Exchange confirmed the delisting of Taizheng Investment Group (one of Asia's largest independent alternative investment management g
-
Baiji Shenzhou's latest response: The allegations in the short report are blatantly false
Time of Update: 2021-03-04
Capital Research, a capital research firm, released a report saying that Baiji state may have "faked" sales.
Notably, Baiji Shenzhou has not responded to seven questions in the short report of J.Capital Research, a capital research firm.
